Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
PHASE2CompletedINTERVENTIONAL
Enrollment
25
Participants
Timeline
Start Date
July 31, 2004
Primary Completion Date
September 30, 2006
Conditions
Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL
alemtuzumab
Given IV
DRUG
methotrexate
Given IV
DRUG
mercaptopurine
Given PO
Trial Locations (1)
91006-3776
COG Phase I Consortium, Arcadia
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00089349 - Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter